Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

This study is testing whether adding TVB-2640 (a drug that blocks a fat-producing enzyme called FASN, which many prostate cancers depend on) to enzalutamide (a standard hormone-blocking drug) can improve outcomes for men with metastatic castration-resistant prostate cancer — meaning the cancer has spread and is no longer responding to standard hormone treatment. **You may be eligible if...** - You are a man over 18 years old with confirmed prostate cancer - Your cancer has spread (metastatic) and is growing despite low testosterone (castration-resistant) - You are planning to start enzalutamide as your first treatment for castration-resistant disease, OR you have previously had only one line of hormone therapy - You are willing to undergo tumor biopsies before and during treatment - Your general health is good (ECOG performance status 0–1) - If you have not had an orchiectomy, you are on testosterone-suppressing injections **You may NOT be eligible if...** - You have already had multiple lines of treatment for castration-resistant prostate cancer - Your organ function (blood, liver, kidneys) is insufficient - You are unable to use contraception during the study Talk to your doctor to see if this trial is right for you.